US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GSK plc ADRhedged

69.79

-0.0140-0.02%

Post-market: 69.790.00000.00%16:10 EDT

Volume:315

Turnover:21.91K

Market Cap:697.95K

PE:- -

High:69.83

Open:69.50

Low:69.38

Close:69.80

52wk High:85.03

52wk Low:55.75

Shares:10.00K

Float Shares:10.00K

Volume Ratio:1.02

T/O Rate:3.15%

Dividend:2.08

Dividend Rate:2.98%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

GSK Expands Treasury Stock Position with June Share Buybacks

GSK Targets Relapsed B-Cell Lymphoma With New Early-Stage Trial

GSK’s ZEAL-1L Lung Cancer Trial Delivers Mixed Readout With Limited Upside for Niraparib

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections

MT Newswires Live

GSK, Spero Therapeutics announce FDA approval of Utebzi

GSK wins first US approval for oral carbapenem to treat complicated UTIs

GlaxoSmithKline (GSK) Gets a Sell from Barclays

Sector Update: Healthcare Stocks Advance in Afternoon Trading

MT Newswires Live

GSK Expands Share Buyback, Lifts Treasury Holding to 6.64% of Voting Rights

GSK Opens New Front in Malaria Prevention With First-in-Human Antibody Trial

GSK announces momelotinib granted ODD from U.S. FDA, EMA

GSK's Clonal Myeloid Disorder Treatment Gets Orphan Drug Designation From US, European Regulators

MT Newswires Live

GSK’s momelotinib wins US and EU orphan status for rare VEXAS syndrome

GSK Advances New COPD Candidate With Completed Phase 1 Ethnic-Sensitivity Study

GSK Executives Acquire Shares Under Company Reward Plan

GlaxoSmithKline's Record $10.6B Nuvalent Acquisition Aims to Revive Its Cancer Drug Business

Europe's Big Pharma Could Win Investors' Favor With Busy End of Year -- Market Talk

GSK US President Acquires Notional ADS Under Executive Savings Plan

GSK's Nuvalent Deal Lays Groundwork for Future Launch of Lung-Cancer Drug -- Market Talk

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/GSKH/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":69.7885,"timestamp":1789502400000,"preClose":69.8025,"halted":0,"volume":315,"hourTrading":{"tag":"盘后","latestPrice":69.7885,"preClose":69.7885,"latestTime":"16:10 EDT","volume":6,"amount":418.731,"timestamp":1789503007262,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00020056588231074523,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"Post-Mkt","change":-0.014,"latestTime":"09-15 17:16:50 EDT","open":69.5,"high":69.83,"low":69.38,"amount":21910,"amplitude":0.006447,"askPrice":104.74,"askSize":200,"bidPrice":34.92,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":69.8025,"nav":66.979706,"aum":669864.039706,"dividendRate":0.029806,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":69.7885,"preClose":69.7885,"latestTime":"16:10 EDT","volume":6,"amount":418.731,"timestamp":1789503007262,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.024724,"impliedVol":0.3521,"impliedVolPercentile":0.9739},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.024724,"shares":10001,"dividePrice":2.0801,"high":69.83,"amplitude":0.006447,"preClose":69.8025,"low":69.38,"week52Low":55.7526,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":69.7885,"eps":0,"divideRate":0.029806,"volume":315,"delay":0,"ttmEps":0,"open":69.5,"prevYearClose":68.2031,"prevWeekClose":66.9705,"prevMonthClose":69.8569,"prevQuarterClose":73.8574,"fiveDayClose":67.5659,"twentyDayClose":69.8844,"sixtyDayClose":71.9341},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645731440","title":"GSK Expands Treasury Stock Position with June Share Buybacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2645731440","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645731440?lang=en_us&edition=fundamental","pubTime":"2026-06-22 22:24","pubTimestamp":1782138247,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK has continued its ongoing share buyback programme, repurchasing more than one mill...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-expands-treasury-stock-position-with-june-share-buybacks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-expands-treasury-stock-position-with-june-share-buybacks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","GSK","GSK.UK","LU1829250122.USD","BK4007","GSKH","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644080970","title":"GSK Targets Relapsed B-Cell Lymphoma With New Early-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644080970","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644080970?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:36","pubTimestamp":1781800606,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The study titled “A Phase 1/2 Open-label, Multi-center Study to Evaluat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-targets-relapsed-b-cell-lymphoma-with-new-early-stage-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-targets-relapsed-b-cell-lymphoma-with-new-early-stage-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4585","GSKH","BK4588","GSK.UK","BK4007","GSK","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644208015","title":"GSK’s ZEAL-1L Lung Cancer Trial Delivers Mixed Readout With Limited Upside for Niraparib","url":"https://stock-news.laohu8.com/highlight/detail?id=2644208015","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644208015?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:30","pubTimestamp":1781800252,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK has reported results for ZEAL-1L, a Phase 3 trial officially titled...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-zeal-1l-lung-cancer-trial-delivers-mixed-readout-with-limited-upside-for-niraparib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-zeal-1l-lung-cancer-trial-delivers-mixed-readout-with-limited-upside-for-niraparib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","BK4588","BK4007","BK4139","GSK","GSKH","LU1829250122.USD","ZEAL","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644723527","title":"Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644723527","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644723527?lang=en_us&edition=fundamental","pubTime":"2026-06-18 00:36","pubTimestamp":1781714160,"startTime":"0","endTime":"0","summary":"First and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatmentiMore than 3 million cases of cUTIs are trea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313706/0/en/Utebzi-tebipenem-pivoxil-approved-in-the-US-for-adults-with-complicated-urinary-tract-infections-cUTIs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","GSKH","GSK.UK","BK4006","BK4585","BK4532","BK4588","AP","LU1829250122.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644740373","title":"GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2644740373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644740373?lang=en_us&edition=fundamental","pubTime":"2026-06-18 00:00","pubTimestamp":1781712056,"startTime":"0","endTime":"0","summary":"GSK  and Spero Therapeutics  said Wednesday that the US Food and Drug Administration has approved Utebzi as treatment for complicated urinary tract infections, including pyelonephritis, in adults.Utebzi, or tebipenem pivoxil, is the first and only oral carbapenem antibiotic approved in the US and is expected to become available by the end of 2026, the companies said.The approval was based on phase 3 trial data showing Utebzi's non-inferiority to intravenous imipenem-cilastatin, with tebipenem pivoxil achieving an overall success rate of 58.5% against 60.2% for imipenem-cilastatin, according to a statement. Tebipenem pivoxil's safety profile is also \"generally similar\" to that of imipenem-cilastatin, the companies said.GSK shares were up about 1%, while Spero stock was down more than 14% in Wednesday trading.Price: 52.72, Change: +0.50, Percent Change: +0.96","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1829250122.USD","SPRO","BK4007","BK4588","BK4139","LABU","LENZ","BK4585","GSK.UK","GSKH","BK4532","BK4539","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644674796","title":"GSK, Spero Therapeutics announce FDA approval of Utebzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2644674796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644674796?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:17","pubTimestamp":1781709438,"startTime":"0","endTime":"0","summary":"GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the Food and Drug Administration has approved Utebzi, an oral antibiotic for the treatme...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-spero-therapeutics-announce-fda-approval-of-utebzi-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-spero-therapeutics-announce-fda-approval-of-utebzi-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","BK4532","GSK","LABU","LU1829250122.USD","SPRO","BK4139","GSK.UK","LENZ","BK4539","BK4588","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644774799","title":"GSK wins first US approval for oral carbapenem to treat complicated UTIs","url":"https://stock-news.laohu8.com/highlight/detail?id=2644774799","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644774799?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:12","pubTimestamp":1781709144,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK and Spero Therapeutics have secured US FDA approval for Utebzi (tebipenem pivoxil)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-wins-first-us-approval-for-oral-carbapenem-to-treat-complicated-utis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-wins-first-us-approval-for-oral-carbapenem-to-treat-complicated-utis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","GSK.UK","LABU","BK4588","GSKH","GSK","LU1829250122.USD","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644060710","title":"GlaxoSmithKline (GSK) Gets a Sell from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2644060710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644060710?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:36","pubTimestamp":1781692578,"startTime":"0","endTime":"0","summary":"Barclays analyst James Gordon CFA maintained a Sell rating on GlaxoSmithKline today and set a price target of £18.00. Gordon CFA covers the Healthc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-gets-a-sell-from-barclays-blurbs-news-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-gets-a-sell-from-barclays-blurbs-news-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSKH","BK4585","GSK","LU1829250122.USD","BK4007","BK4588","BK4532","CFA","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644761439","title":"Sector Update: Healthcare Stocks Advance in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2644761439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644761439?lang=en_us&edition=fundamental","pubTime":"2026-06-17 01:29","pubTimestamp":1781630950,"startTime":"0","endTime":"0","summary":"Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF  each adding 0.2%.The iShares Biotechnology ETF  was down 0.2%.In corporate news, GSK  said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares rose 0.3%.Novo Nordisk  plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wegovy, within the next few months, Reuters reported, citing Chief Executive Mike Doustdar. According to the report, Eli Lilly  submitted a marketing application in China for its oral obesity drug late last year, putting the company ahead of Novo in the race to launch a weight-loss pill in the country. Novo shares were down 0.3%, and Lilly was 0.1% lower.Oncolytics Biotech  shares jumped past 10% after it said Tuesday it has received a US pate","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0432979614.USD","LU0689472784.USD","LU2168564222.USD","LU0823416689.USD","LU0079474960.USD","LU2265009873.SGD","LU0456855351.SGD","LU1061106388.HKD","LU0198837287.USD","LU0256863902.USD","IE0002141913.USD","LU0889565916.HKD","LU0154236417.USD","LU0323591593.USD","LU0316494557.USD","IE00B7KXQ091.USD","NVO","LU0354030438.USD","LU0203201768.USD","LU2108987350.USD","LU0640476718.USD","SG9999015986.USD","LU1548497426.USD","LU1035775433.USD","IE00BZ1G4Q59.USD","IE00BFTCPJ56.SGD","LU1232071149.USD","LU2237443622.USD","LU0096364046.USD","LU0882574139.USD","LU2237443549.SGD","LU0133085943.USD","LU2361044865.SGD","SGXZ51526630.SGD","BK4532","LU0266013472.USD","IE00B4JS1V06.HKD","IE00BKPKM429.USD","LU2023250504.SGD","LU2491049909.HKD","BK4007","LU1064131342.USD","LU2089284900.SGD","LU2361044949.HKD","LU2552382058.USD","IE00B2B36J28.USD","LU1267930730.SGD","LU1988902786.USD","LU2089984988.USD","SG9999015952.SGD","LU1712237335.SGD","LU0256863811.USD","LU2471134523.USD","LU0820561909.HKD","SG9999014906.USD","LU1069344957.HKD","SG9999014898.SGD","LU1814569148.SGD","LU2211815571.USD","IE00BJT1NW94.SGD","ELIS","LU1917777945.USD","IE0001KFT4U8.USD","LU0289739699.SGD","IE00B4R5TH58.HKD","SG9999014880.SGD","LU0097036916.USD","LU0683600562.USD","LU1057294990.SGD","LU2324357040.USD","LU2750360997.AUD","LU2471134879.HKD","LU1291159041.SGD","LU0109391861.USD","LLII","LU2756315318.SGD","LU2357305700.SGD","LU2168564065.EUR","LU0823434740.USD","LU2237443465.HKD","LU2750360641.GBP","LU2168563687.JPY","LU1551013425.SGD","GSK","LU2089283258.USD","LU2462157665.USD","LU1868836914.USD","LU0114720955.EUR","SGXZ57979304.SGD","GSKH","LU2111349929.HKD","LU0417517546.SGD","NVOX","LU2491050154.USD","LLYZ","LU0106261372.USD","LLY","LU0708995401.HKD","SG9999017495.SGD","LU2028103732.USD","LU2271345857.HKD","LU1145028129.USD","LU2360106947.USD","LU1974910355.USD","LU1829250122.USD","LU2417539215.USD","LU2746668974.SGD","LU0225283273.USD","LU0353189763.USD","LU0820561818.USD","LU2112291526.USD","LU0823434583.USD","LU2264538146.SGD","LU2552382215.SGD","SG9999018857.SGD","LU0061475181.USD","LU1323610961.USD","LU2023250330.USD","LU0006306889.USD","IE00B775H168.HKD","IE0004445015.USD","LU2106854487.HKD","LU0471298694.HKD","LU2461242641.AUD","LU0466842654.USD","LU1983299246.USD","LU0320765059.SGD","LU2237443895.HKD","LU0158827948.USD","LU1868836757.USD","LU0122379950.USD","LU0354030511.USD","LU0471298777.SGD","LU2023251221.USD","BK4585","LU1989771016.USD","LU2237443382.USD","LU1093756325.SGD","LU0238689110.USD","SG9999001176.USD","IE00BKDWB100.SGD","LU1127390331.HKD","LU2756315664.SGD","IE0004445239.USD","LU1720051017.SGD","SGXZ31699556.SGD","LU0094547139.USD","LU0210536198.USD","LU0820562030.AUD","LU2213496289.HKD","LU2746668461.USD","LU1093756168.USD","LU2063271972.USD","LU1280957306.USD","IE00BK4W5M84.HKD","LU2361045086.USD","LU2471134796.USD","LU0787776722.HKD","GSK.UK","LU0964807845.USD","LU2168564149.EUR","LU0234572021.USD","LU0353189680.USD","SG9999015945.SGD","LU0203202063.USD","SG9999015978.USD","IE00BFSS7M15.SGD","IE00BJJMRZ35.SGD","LU1868837136.USD","LU0109394709.USD","LU0385154629.USD","SGXZ81514606.USD","BK4581","BK4588","LU2168564495.EUR","LU0786609619.USD","BK4599","IE00BFSS8Q28.SGD","LU0158827781.USD","LU0320765992.SGD","LU2552382132.HKD","LU1629891620.HKD","BK4139","SGXZ99366536.SGD","LU1720051108.HKD","ELIL","GB00BDT5M118.USD","LU1868837300.USD","SG9999014914.USD","IE00BN29S564.USD","IE0005OL40V9.USD","LU1623119135.USD","LLYX","BK4516","BK4534","LU1868836591.USD","ONCY","LU0672654240.SGD","IE00B1BXHZ80.USD","LU2468319806.SGD","LU2896262040.SGD","LU0058720904.USD","LU0882574055.USD","LU1551013342.USD","SG9999018865.SGD","LU1366192091.USD","IE00B1XK9C88.USD","IE00BJJMRX11.SGD","IE00BWXC8680.SGD","IE0009355771.USD","SG9999001176.SGD","NVOH","IE00BK4W5L77.USD","LU2237443978.SGD","LU2456880835.USD","LU2471134952.CNY","BK4533","SG9999013999.USD","LU0943347566.SGD","IE00BJLML261.HKD","LU2236285917.USD","LU2237438978.USD","LU1804176565.USD","IE00BJJMRY28.SGD","LU2602419157.SGD","LU2087625088.SGD","LU2491050071.SGD","IE00BKVL7J92.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643201675","title":"GSK Expands Share Buyback, Lifts Treasury Holding to 6.64% of Voting Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2643201675","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643201675?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:01","pubTimestamp":1781532116,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has continued to execute its existing share buyback programme, repurchasing more than 1.1 m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-expands-share-buyback-lifts-treasury-holding-to-6-64-of-voting-rights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-expands-share-buyback-lifts-treasury-holding-to-6-64-of-voting-rights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","GSK.UK","BK4585","GSK","BK4532","GSKH","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643944592","title":"GSK Opens New Front in Malaria Prevention With First-in-Human Antibody Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643944592","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643944592?lang=en_us&edition=fundamental","pubTime":"2026-06-13 00:31","pubTimestamp":1781281877,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK has launched a first-in-human trial of its new antibody GSK4425689A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-opens-new-front-in-malaria-prevention-with-first-in-human-antibody-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-opens-new-front-in-malaria-prevention-with-first-in-human-antibody-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1829250122.USD","GSK","BK4007","BK4532","BK4585","GSK.UK","BK4588","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642267278","title":"GSK announces momelotinib granted ODD from U.S. FDA, EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2642267278","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642267278?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:07","pubTimestamp":1781262453,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced that momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation, ODD, from th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-announces-momelotinib-granted-odd-from-u-s-fda-ema-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-announces-momelotinib-granted-odd-from-u-s-fda-ema-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4081","GSK.UK","ODD","IE0009354923.USD","BK4588","BK4007","GSKH","LU1829250122.USD","BK4183","EMA","BK4532","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642269788","title":"GSK's Clonal Myeloid Disorder Treatment Gets Orphan Drug Designation From US, European Regulators","url":"https://stock-news.laohu8.com/highlight/detail?id=2642269788","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642269788?lang=en_us&edition=fundamental","pubTime":"2026-06-12 17:31","pubTimestamp":1781256686,"startTime":"0","endTime":"0","summary":"GSK's  momelotinib has received orphan drug designation from the US Food and Drug Administration and the European Medicines Agency for the treatment of the VEXAS syndrome, the company said on Friday.VEXAS syndrome is a severe, progressive condition with no approved treatments and a 30% to 40% five-year mortality rate, it added.The British pharmaceutical giant has planned a phase II/III trial to evaluate the efficacy and safety of momelotinib in VEXAS syndrome that will support upcoming global regulatory submissions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU1829250122.USD","GSKH","BK4007","GSK.UK","BK4585","GSK","EPV","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642524242","title":"GSK’s momelotinib wins US and EU orphan status for rare VEXAS syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2642524242","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642524242?lang=en_us&edition=fundamental","pubTime":"2026-06-12 14:08","pubTimestamp":1781244512,"startTime":"0","endTime":"0","summary":"An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has secured Orphan Drug Designation from both the U.S. and European regula...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-momelotinib-wins-us-and-eu-orphan-status-for-rare-vexas-syndrome?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-momelotinib-wins-us-and-eu-orphan-status-for-rare-vexas-syndrome?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK","GSK.UK","GSKH","BK4007","BK4532","LU1829250122.USD","BK4156","BK4585","EPV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642223519","title":"GSK Advances New COPD Candidate With Completed Phase 1 Ethnic-Sensitivity Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2642223519","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642223519?lang=en_us&edition=fundamental","pubTime":"2026-06-12 00:30","pubTimestamp":1781195410,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1, Randomized, Placebo-Controlled, Double-Bl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-advances-new-copd-candidate-with-completed-phase-1-ethnic-sensitivity-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-advances-new-copd-candidate-with-completed-phase-1-ethnic-sensitivity-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK","BK4585","LU1829250122.USD","GSKH","BK4588","GSK.UK","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642238340","title":"GSK Executives Acquire Shares Under Company Reward Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2642238340","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642238340?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:33","pubTimestamp":1781188391,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK disclosed that several senior executives, including President Europe Lynn Baxter an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-executives-acquire-shares-under-company-reward-plan-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-executives-acquire-shares-under-company-reward-plan-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","GSK","BK4007","BK4532","BK4585","BK4588","LU1829250122.USD","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139063928","title":"GlaxoSmithKline's Record $10.6B Nuvalent Acquisition Aims to Revive Its Cancer Drug Business","url":"https://stock-news.laohu8.com/highlight/detail?id=1139063928","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139063928?lang=en_us&edition=fundamental","pubTime":"2026-06-11 16:01","pubTimestamp":1781164860,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline PLC (GSK.US) has accelerated the rebuilding of its cancer drug portfolio with a record-breaking $10.6 billion acquisition of US biotech firm Nuvalent, Inc. (NUVL). This move is...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LU2237443549.SGD","LU2236285917.USD","LU2237443382.USD","LU2237443622.USD","IE00B3T34201.USD","LU0289739699.SGD","AZNH","GSK.UK","BK4568","BK4139","LU2237443465.HKD","LU0889565916.HKD","NUVL","GSK","BK4585","LU2417539215.USD","LU2456880835.USD","LU2462157665.USD","LU2237443978.SGD","LU0320765992.SGD","BK4532","BK4007","GSKH","LU0058720904.USD","AZN","LU2237443895.HKD","LU0109394709.USD","BK4588","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642424085","title":"Europe's Big Pharma Could Win Investors' Favor With Busy End of Year -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2642424085","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642424085?lang=en_us&edition=fundamental","pubTime":"2026-06-10 22:34","pubTimestamp":1781102040,"startTime":"0","endTime":"0","summary":"1434 GMT - Big European pharmaceutical companies have a busy second half of the year, with several key events that could help them build positive outlooks and win investors' favor, Bank of America analysts say in a note. Novartis and AstraZeneca have the busiest schedules in terms of results of clinical studies, the analysts say. At GSK and Sanofi, recently appointed CEOs are expected to provide updates on their plans alongside second-quarter earnings, they add. For Novo Nordisk, the main focus remains on prescription trends for its obesity and diabetes products, BofA says. Roche faces a quieter second half, but the launch of its new breast-cancer drug giredestrant will be key, the analysts write. The Stoxx Europe 600 Health Care index is up 0.5%. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443549.SGD","RHHBY","BK4568","BK4007","LU2237443622.USD","LU1093756325.SGD","LU2417539215.USD","IE00B4R5TH58.HKD","LU0208291251.USD","NVOX","NVS","03165","IE00BFTCPJ56.SGD","BK4585","AZNH","IE00BJT1NW94.SGD","LU0889565916.HKD","LU1829250122.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","BK4532","LU0058720904.USD","LU0070302665.USD","AZN","GSK","LU2236285917.USD","LU2462157665.USD","LU0154236417.USD","IE00B2B36J28.USD","LU2237443895.HKD","LU2237443382.USD","BK4588","IE0002141913.USD","LU2237443465.HKD","NVO","IE0009355771.USD","LU0211331839.USD","LU0289739699.SGD","IE00B3T34201.USD","GSK.UK","LU0320765992.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD","LU2237443978.SGD","LU2456880835.USD","GSKH","LU0109394709.USD","BK4578","BK4599","NVOH","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442409","title":"GSK US President Acquires Notional ADS Under Executive Savings Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442409","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642442409?lang=en_us&edition=fundamental","pubTime":"2026-06-10 22:32","pubTimestamp":1781101947,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK disclosed that Maya Martinez-Davis, its President of U.S. operations, acquired noti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-us-president-acquires-notional-ads-under-executive-savings-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-us-president-acquires-notional-ads-under-executive-savings-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1829250122.USD","BK4007","BK4588","BK4585","GSK.UK","GSKH","BK4532","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642429069","title":"GSK's Nuvalent Deal Lays Groundwork for Future Launch of Lung-Cancer Drug -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2642429069","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642429069?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:29","pubTimestamp":1781098140,"startTime":"0","endTime":"0","summary":"1329 GMT - GSK's proposed acquisition of Nuvalent is a strong fit for the U.K. drugmaker and lays the groundwork for the future launch of its lung-cancer drug ris-rez, UBS analysts say in a research note. The deal adds two drugs for lung cancer at a late stage of development to GSK's pipeline and sets the foundation for the infrastructure the company would have had to build to launch ris-rez, the analysts say. The two Nuvalent drugs have potential to generate peak sales of $3.75 billion combined by improving the efficacy and tolerability of existing treatments, UBS says. \"We expect rapid uptake in late-line settings with potential in earlier lines if tolerability advantages play out,\" the analysts add. GSK shares are broadly flat.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","BK4532","BK4588","BK4007","LU1829250122.USD","BK4539","GSK.UK","GSKH","BK4139","BK4585","NUVL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}